News|Slideshows|April 10, 2026

AAD Issues First Pediatric Atopic Dermatitis Guidelines

Author(s)Maddi Hebebrand, MC, Associate Editor

Listen

0:00 / 0:00

The guidelines formalize a stepwise treatment approach ranging from emollients and topical steroids to systemic therapies.

References

American Academy of Dermatology issues first-ever pediatric atopic dermatitis guidelines, highlighting prevention strategies and effective treatments. News release. American Academy of Dermatology. April 7, 2026. Accessed April 10, 2026. https://www.aad.org/news/aad-issues-first-pediatric-atopic-dermatitis-guidelines
Davis DMER, Alikhan A, Bercovitch L, et al. Guidelines of care for the management of atopic dermatitis in pediatric patients. JAAD. 2026. doi:10.1016/j.jaad.2026.02.113
Gür Çetinkaya P, Şahiner ÜM. Childhood atopic dermatitis: current developments, treatment approaches, and future expectations. Turk J Med Sci. 2019;49(4):963-984. Published 2019 Aug 8. doi:10.3906/sag-1810-105

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Related to this article

October 9th, 2026

Day 2 Recap: Fall Clinical 2026

The second day of Fall Clinical 2026 brought new psoriasis data on ixekizumab plus tirzepatide and 2-year icotrokinra results, along with 3-year nemolizumab findings, upadacitinib switch data, and expert guidance on choosing a biologic in atopic dermatitis.

October 9th, 2026

No Observed Skin Lesion Flares After Switching to Upadacitinib in Atopic Dermatitis

No skin lesion flares were observed through 16 weeks after switching from dupilumab to upadacitinib; itch flares occurred in 3.6% to 4.8% of patients with baseline WP-NRS scores of 6 or lower.

October 9th, 2026

Nemolizumab Maintains Deep Skin and Itch Responses Through 3 Years in Atopic Dermatitis

Three-year ARCADIA LTE data show sustained skin clearance and itch control with nemolizumab in moderate-to-severe atopic dermatitis.

October 9th, 2026

Icotrokinra Maintains Skin Clearance Through 2 Years in Phase 3 ICONIC-LEAD

At week 112, at least 72% of patients on icotrokinra held PASI 90 and at least 44% held PASI 100, with no new safety signals reported.

October 9th, 2026

Remibrutinib Approval Brings First On-Label Option for Symptomatic Dermographis

Raj Chovatiya, MD, PhD, MSCI, discusses the FDA approval of remibrutinib for symptomatic dermographism and what an on-label option means for patients.

October 9th, 2026

Ixekizumab Plus Tirzepatide Shifts Biomarkers in Psoriasis with Obesity

By week 36, combination therapy altered 482 proteins and 467 genes vs 140 and 16 with ixekizumab alone in exploratory TOGETHER-PsO data.

October 8th, 2026

Upadacitinib Shows Broader Inflammatory Effects and Earlier Skin Barrier Restoration Than Dupilumab in Atopic Dermatitis

Upadacitinib showed broader inflammatory effects and earlier skin barrier restoration than dupilumab in atopic dermatitis.

October 8th, 2026

Biofrontera Submits sNDA to Expand Ameluz PDT for Actinic Keratoses Across the Body

The supplemental New Drug Application seeks to expand the use of Ameluz with red light photodynamic therapy beyond the face and scalp to actinic keratoses on the extremities, neck, and trunk.

AAD Issues First Pediatric Atopic Dermatitis Guidelines

Related to this article

Trending on Dermatology Times

Ixekizumab Plus Tirzepatide Shifts Biomarkers in Psoriasis with Obesity

Nemolizumab Maintains Deep Skin and Itch Responses Through 3 Years in Atopic Dermatitis

Upadacitinib Shows Broader Inflammatory Effects and Earlier Skin Barrier Restoration Than Dupilumab in Atopic Dermatitis

No Observed Skin Lesion Flares After Switching to Upadacitinib in Atopic Dermatitis

Icotrokinra Maintains Skin Clearance Through 2 Years in Phase 3 ICONIC-LEAD